Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study

Published:2018-09 Issue: Volume:100 Page:1-7
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sheng Xinan,Cao Dengfeng,Yuan Jianlin,Zhou Fangjian,Wei Qiang,Xie Xiaodong,Cui Chuanliang,Chi Zhihong,Si Lu,Li Siming,Mao Lili,Lian Bin,Tang Bixia,Yan Xieqiao,Wang Xuan,Kong Yan,Dai Jie,Bai Xue,Zhou Li,Guo Jun

Funder

Beijing Talents Fund

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support

Beijing Municipal Science and Technology Commission

Bayer Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Uncommon and recently described renal carcinomas;Srigley;Mod Pathol,2009

2. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan;Tokuda;J Urol,2006

3. Collecting duct renal cell carcinoma: a matched analysis of 41 cases;Karakiewicz;Eur Urol,2007

4. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship;Gupta;Am J Surg Pathol,2012

5. Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) Study;Oudard;J Urol,2007

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney;Clinical Genitourinary Cancer;2024-08

2. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma;Therapeutic Advances in Urology;2024-01

3. Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options;International Journal of Cancer;2023-10-12

4. Advances in targeted therapy and immunotherapy for melanoma (Review);Experimental and Therapeutic Medicine;2023-07-13

5. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24);European Journal of Cancer;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3